|Daily Range||$34.20 - $34.35|
|52-Week Range||$33.23 - $38.71|
|Dividend (Yield)||$0.00 (2.7%)|
|Average Daily Volume||1,268,459|
|Current FY EPS||$1.95|
News & Commentary
These three value stocks have been beaten up recently, but there's a chance they may not stay near their 52-week lows for much longer.
I’d prefer coal in my stocking to these three troubled biotech stocks.
Three Motley Fool contributors tell us what they think were the biggest drug trial failures this year.
ImmunoGen shares lose half their value following an update on a key breast cancer drug trial. Find out whether today's swoon could mark a buying opportunity.
Not all stocks had a great 2014. Here are three stocks that could be ready for a comeback.
A recent World Health Organization study shows that this growing problem is responsible for nearly a half-million cancer diagnoses each year.
A recently released study from Canada shines light on the advancements made in treating breast cancer over the past two decades.
Inovio Pharmaceuticals stock dips by double-digits in November after the company witnesses a key licensing deal with a major pharmaceutical company come to an end.
This high-yield dividend stock may be paying out north of 7%, but its long-term outlook might have investors wisely running in the opposite direction.
This 3D bioprinting company finally has a product on the market.